Capricor Therapeutics Inc...

AI Score

0

Unlock

14.49
-0.41 (-2.75%)
At close: Jan 23, 2025, 3:59 PM
14.60
0.76%
After-hours Jan 23, 2025, 06:53 PM EST
undefined%
Bid 14.25
Market Cap 658.86M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.02
PE Ratio (ttm) -14.21
Forward PE n/a
Analyst Buy
Ask 15.1
Volume 490,100
Avg. Volume (20D) 1,269,403
Open 14.64
Previous Close 14.90
Day's Range 14.21 - 14.86
52-Week Range 3.52 - 23.40
Beta undefined

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2007
Employees 101
Stock Exchange NASDAQ
Ticker Symbol CAPR

Analyst Forecast

According to 7 analyst ratings, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 124.29% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Capricor Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $9.87M, reflecting a -18.35% YoY shrinking and earnings per share of -0.09, making a 350.00% increase YoY.
2 months ago
+9.34%
Capricor Therapeutics shares are trading higher af... Unlock content with Pro Subscription
3 months ago
+9.07%
Capricor Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a price target of $35.